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Background: Metabolism of human chorionic gonado-
tropin (hCG) in the serum and kidney yields the termi-
nal urinary product hCG b-core fragment (hCGbcf),
comprising two disulfide-linked peptides (b6-b40 and
b55-b92) of which one (b6-b40) retains truncated N-
linked sugars. Hyperglycosylated hCGbcf may indicate
choriocarcinoma or Down syndrome, but the glycosyla-
tion profile of hCGbcf has not been thoroughly evalu-
ated.
Methods: hCGbcf, purified from pregnancy urine, was
reduced by “on-target” dithiothreitol (DTT) reduction
and analyzed by matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry (MALDI-TOF
MS). The mass ([M1H]1) of the primary sequence of the
glycosylated peptide b6-b40 was subtracted from the
m/z values of the discrete peaks observed to give the
masses of the carbohydrate moieties. Carbohydrate
structure was predicted by sequentially subtracting the
masses of the monosaccharide residues corresponding
to N-linked carbohydrates of the hCG b-subunit re-
ported in the literature.
Results: Mass spectra of hCGbcf revealed a broad triple
peak at m/z 8700–11300. After reduction, the triple peak
was replaced by a discrete set of peaks between m/z 4156
and 6354. A peak at m/z 4156.8 corresponded to the
nonglycosylated peptide (b55-b92). The remaining nine
peaks indicated that urinary hCGbcf comprises a set of
glycoforms smaller and larger than the trimannosyl
core.
Conclusions: hCGbcf comprises a wider set of glyco-
forms than reported previously. Peaks of highest mass
indicate evidence of hyperglycosylated carbohydrate
moieties. The data support previous reports that
hCGbcf oligosaccharides lack sialic acid and galactose
residues. No indication was found of a b6-b40 peptide
that was entirely devoid of carbohydrate.
© 2000 American Association for Clinical Chemistry
The heterodimeric placental hormone human chorionic
gonadotropin (hCG)3 is a widely studied member of the
glycoprotein hormone family that includes luteinizing
hormone, thyroid-stimulating hormone, and follicle-stim-
ulating hormone. Each consists of a common a subunit
and a unique b subunit that confers specific hormonal
activity. hCG sustains early pregnancy by binding lutein-
izing hormone receptors at the corpus luteum surface and
stimulating progesterone secretion until the placenta is
able to carry out this function itself. In addition to being
universally used as an early marker of pregnancy, hCG is
monitored in sports drug testing (1 ). The hCG b-subunit
(hCGb) is also a marker of various epithelial and gesta-
tional trophoblast carcinomas (2, 3), where it may exert
independent stimulatory activity (4, 5). The precise struc-
ture of hCG has been well characterized by HPLC-mass
spectrometry (6, 7) and by crystallographic analysis (8, 9).
Peptide mass mapping by matrix-assisted laser de-
sorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS), using trypsin for digestion, has also
been found to be a suitable technique for the identification
of hCG and its subunits (10, 11).
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hCG, in common with other glycoprotein hormones, is
characterized by sugar moieties on both subunits that
determine receptor affinity and metabolic clearance. The
currently accepted structural model of the N-linked car-
bohydrates found on hCGb is of a complex biantennary
moiety terminating in sialic acid based on a trimannosyl
core (12 ). Despite the model, wide carbohydrate hetero-
geneity has been found. Mono-, bi-, and triantennary
N-linked sugars occur in hCGb in both normal and
abnormal pregnancies as well as in choriocarcinomas
(12–17). An increase in the triantennary form seems to be
a feature indicative of an abnormal state and may be of
diagnostic value. In normal pregnancies, Elliott et al. (14 )
found that the biantennary form accounted for 76.5% of
the N-linked oligosaccharide content of urinary hCGb,
that 21.6% was triantennary, and that the remainder was
monoantennary (Fig. 1). In gestational choriocarcinoma,
by contrast, the triantennary content accounted for up to
63.6% of the total. A similar increase in hCG hyperglyco-
sylation has been detected in Down syndrome by Cole et
al. (18 ). Indeed, an ELISA for hyperglycosylated hCG has
been developed based on a monoclonal antibody raised to
the hyperglycosylated variant (19, 20). Prenatal diagnos-
tic testing of maternal urine based on this ELISA is
claimed to detect up to 97% of Down syndrome cases with
a 5% false-positive rate when modeled with values of
other markers (21 ).
Similarly, carbohydrate heterogeneity remains in the
terminal urinary degradation product of the b-subunit,
the hCG b-core fragment (hCGbcf). This core fragment
has a primary structure of 73 amino acids, consisting of
two polypeptides: b6-b40 and b55-b92, joined by four
cystine residues (Fig. 2). Only the b6-b40 chain is glyco-
sylated, retaining the two complex N-glycans linked to
asparagine residues 13 and 30. However, as a conse-
quence of metabolism, these branched chain carbohy-
drates are truncated. Various studies of the carbohydrate
structure of hCGbcf using a combination of immunoaf-
finity, gel-filtration, and ion-exchange chromatography,
glycosidase digestion, hydrazinolysis, and periodate oxi-
dation have been reported (22–26). A population of
shortened mono- and biantennary carbohydrate cores has
been suggested, which may or may not be fucosylated
(22 ). There is disagreement over whether these moieties
possess sialic acid or galactose residues, although there is
some evidence that they do extend beyond the trimanno-
syl cores (24 ). In an attempt to help resolve this disagree-
ment, we investigated the structural variation in these
oligosaccharide moieties, using an alternative approach
that incorporates analysis by MALDI-TOF MS.
MALDI-TOF MS is a powerful tool for determining the
mass of macromolecules, as first reported by Karas and
Hillenkamp (27 ), yielding signals that correspond mainly
to singly charged molecular ions. Chemical or enzymatic
cleavage of posttranslationally modified proteins, fol-
lowed by MALDI-TOF MS analysis, has been used for the
purpose of structural characterization. Exoglycosidase
digestion with MALDI-TOF MS analysis has been used to
elucidate carbohydrate sequences and composition of
glycoproteins (28 ). Nonetheless, at first glance, this ap-
proach appears to be overcomplicated for investigating
the glycoforms of hCGbcf, particularly because the
branch chain sequence is unlikely to be affected by
metabolism of the b-subunit, albeit that the chain is
truncated. Indeed, exoglycosidase digestion could con-
found interpretation of results because absolute specific-
ity for one substrate is rare and this may possibly lead to
the presence of artifacts. However, direct analysis of
hCGbcf by low-resolution MALDI-TOF MS is not suffi-
ciently discriminating to identify individual glycoforms
because of the lack of resolution between them. A simple
but potentially useful approach could be to reduce the
disulfide bonds, e.g., with DTT, to yield the two separate
polypeptide chains before analysis. Separation of the
b55-b92 chain, which is of no diagnostic value, from the
b6-b40 chain is advantageous because the overall masses
of the glycoproteins being analyzed are reduced, which is
conducive to discriminating between them. The mass of
each glycosylation variant on the b6-b40 chain can then be
determined by calculating the difference in mass between
each peak observed to the mass of its corresponding
primary amino acid sequence, i.e., nonglycosylated b6-
b40. The presence of residual triantennary sugars on
hCGbcf has not been as well determined as for free hCGb
but should be characterized to determine any diagnostic
potential. In this study, we used MALDI-TOF MS, for the
first time, to directly observe and determine the number
of glycoforms in a purified sample of pooled pregnancy
hCGbcf.
Materials and Methods
materials
The hCGbcf used in this study was isolated from crude
urinary hCG (Sigma) and characterized previously (29 ).
DTT, for the reduction of disulfide bonds, and NH4HCO3
Fig. 1. Structures of the asialo asparagine-linked oligosaccharides of
the hCGb subunit from normal pregnancy, hydatidiform mole, chorio-
carcinoma (I, III, and IV, respectively), and gestational diabetes (II).
Adapted from Elliott et al. (14).
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were obtained from Sigma-Aldrich. The MALDI-TOF MS
matrix 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic
acid; SA) was also purchased from Sigma-Aldrich and
used without further purification. Acetonitrile and triflu-
oroacetic acid (TFA) were of analytical grade and ob-
tained from Merck.
maldi-tof ms
To acquire spectra of the nonreduced molecule, we ap-
plied 0.5 mL of hCGbcf [20 mmol/L in distilled, deionized
H2O (dH2O)] to a stainless steel MALDI-TOF MS target
and mixed it with 1.0 mL of SA [20 g/L in 70:30 (by
volume) acetonitrile-1 mL/L TFA in dH2O] and air dried.
The instrument was calibrated externally using horse
heart cytochrome C (Mr 12 360.1; Sigma-Aldrich). Spectra
of reduced glycoforms were obtained by first mixing, on
a MALDI-TOF MS target, 0.5 mL of hCGbcf (20 mmol/L in
dH2O) with 0.5 mL of DTT (100 mmol/L in 100 mmol/L
NH4HCO3, pH 8.8) (30 ). When this mixture was virtually
dry, 0.5 mL of 1 mL/L TFA in dH2O was added to the
remaining droplet. After the mixture was again allowed
to partially dry, 1.0 mL of SA [20 g/L in a 70:30 mixture
(by volume) of acetonitrile-1 mL/L TFA in dH2O] was
added, and the sample was air-dried as before. Mass
spectrometric analysis was carried out on VG TofSpec E
(Micromass) and LaserMAT 2000 (Finnigan MAT) instru-
ments, with 1.5 m and 0.5 m flight tubes, respectively, and
both operating at an accelerating voltage of 20 kV. A
pulsed nitrogen laser (lmax 5 337 nm) was used to desorb
ions from the samples, which were detected by a micro-
channel plate detector at a sampling rate of 500 MHz.
Spectra were generated by summing 30–40 laser shots.
Data were acquired from both instruments operating in
the positive linear mode.
treatment of results
Initially, the peak relating to the nonglycosylated hCGbcf
peptide (b55-b92) was internally calibrated to the average
molecular mass of its given primary sequence, [M1H]1
4156.8 (calculated using the Protein Abacus computer
software; Finnigan MAT). This facilitated the automatic
correction of the mass values of the remaining peaks to
their correct values.
To determine the inferred mass values of the hCGbcf
carbohydrate moieties, we subtracted the average molec-
ular mass ([M1H]1 3752.4) of the primary sequence of the
glycosylated hCGbcf polypeptide (b6-b40) from the mass
([M1H]1) values of the acquired peaks (Table 1). The
carbohydrate content of these peaks was then deduced by
the sequential subtraction of the masses of the sugar
residues present in hCG b-subunit carbohydrates (Table
2). Carbohydrate structures (Table 3) could then be pre-
dicted from the deduced monosaccharide content, taking
into account the very small difference between the calcu-
lated and the observed masses (#0.15%). Different com-
binations of carbohydrate structures are shown where the
mass of a peak indicated several monosaccharides from
which several permutations could be construed. Al-
though this study did not yield any conformational infor-
mation, the anomeric glycosidic linkages within the car-
bohydrate structures in Table 3 have been described
previously (14 ) and were used in our analysis.
Results
SA was selected as the MALDI-TOF MS matrix of choice
for this investigation because other standard matrices
used in protein analysis, a-cyano-4-hydoxycinnamic acid
and sDHB [a 9:1 (by weight) mixture of 2,5-dihydroxy-
benzoic acid and 5-methoxysalicylic acid], did not yield
intense spectra for hCGbcf (data not shown). A typical
spectrum of hCGbcf obtained by MALDI-TOF MS using
SA is shown in Fig. 3. The spectrum is characterized by a
broad triple peak at m/z 8700–11300 with discernible
peaks at m/z 9110, 9930, and 10770. After reduction with
DTT (Fig. 4), the triple peak disappeared and was re-
placed by a set of resolved peaks between m/z 4156 and
Fig. 2. Schematic diagram of the primary amino acid sequence of hCGbcf, showing positions of disulfide bonds and N-linked carbohydrates.
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6354. The initial peak (Fig. 4), at m/z 4164.2, was presumed
to arise from the nonglycosylated hCGbcf peptide chain
(b55-b92) because the m/z value is within the 0.5% error
allowed for the linear mode of the MALDI instrument. To
obtain corrected values for the remaining peaks, this peak
was internally calibrated to the average molecular mass of
the given primary sequence, [M1H]1 4156.8 (calculated
using the Protein Abacus computer software). Despite the
fact that hCGbcf asparagine-linked carbohydrate moieties
were not observed directly, the low percentage errors
between the observed and the expected mass values of the
peaks acquired show that it is likely that real glycoforms
were detected (Table 1).
Carbohydrate moieties, shown in Table 3, were deter-
mined as described above. Peak 1 (m/z 4630.2) arises from
a polypeptide possessing a single truncated and fucosy-
lated monoantennary oligosaccharide (Man2GlcNAc2Fuc)
with a predicted mass of 876.8, whereas the polypeptide
giving rise to peak 2 (m/z 4819.6) has two shortened
fucosylated monoantennary sugars (ManGlcNAc2Fuc and
GlcNAc2Fuc) with a predicted mass of 1064.0. Peaks 6
(m/z 5677.9) and 7 (m/z 5821.1) apparently arise from
hCGbcf glycoforms containing two N-linked trimannosyl
core carbohydrates (Man3GlcNAc2). In peak 6, a single
trimannosyl core possesses fucose (with a predicted mass
of 1931.8), whereas both are fucosylated in peak 7 (with a
predicted mass of 2077.9). The combination of monosac-
charide residues (with a predicted mass of 2420.3) that
make up the glycoform observed at peak 8 (m/z 6179.0) can
be configured to produce an identical pair of sugar struc-
tures that are shortened versions (GlcNAc2Man2GlcNAc2) of
carbohydrate structures II or IV found by Elliott et al. (14 ).
The number of monosaccharide residues calculated for
the polypeptides giving mass spectral peaks 3–5 and peak
9 precludes the determination of a single pair of glyco-
forms, and for these alternative structures have been
suggested. The predicted mass of 1242.2 for the carbohy-
drate moiety of the glycoform at peak 3 (m/z 5000.8)
indicates either a single fucosylated trimannosyl core
attached to a monoantennary N-acetylglucosamine
(Man3GlcNAc3Fuc) or a trimannosyl core (Man3GlcNAc2)
at one glycosylation site and a single GlcNAc at the other,
one of which is fucosylated. Peak 4 (m/z 5358.2) indicates
a glycoform with a predicted carbohydrate mass of 1607.5,
which can translate to two shortened core sugars
(Man2GlcNAc2) differing by a fucose residue. An alterna-
tive combination includes a trimannosyl core and a short-
ened core (ManGlcNAc2), one of which is fucosylated.
Similarly, the predicted carbohydrate mass (1769.6) for
the glycoform seen at peak 5 (m/z 5517.6) indicates a
monosaccharide content from which may be constructed
a trimannosyl core (Man3GlcNAc2) and a truncated core
oligosaccharide (Man2GlcNAc2), one of which is con-
nected to a fucose residue. Finally, two extended triman-
nosyl cores (Man3GlcNAc4) can be inferred from a pre-
dicted carbohydrate mass of 2598.4 of the glycopeptide at
peak 9 (m/z 6353.8). Structures construed from this mass
may be pairs or a combination of truncated oligosaccha-
rides II, III, or IV in Fig. 1. There is an additional peak in
the mass spectra of DTT-reduced hCGbcf between peaks
3 and 4 that we assume to be an additional glycoform but
for which the data analysis software was unable to
acquire a value.
Discussion
Direct carbohydrate analyses of hCGbcf in previous stud-
ies have generally suggested that the metabolite retains
shortened hCGb asparagine-linked oligosaccharides that
Table 1. Peptides of hCGbcf released after DTT reduction, detected by MALDI-TOF MS.
Peak
Observed
mass, M1H1
Mass of inferred primary
sequence, M1H1a
Mass 2 primary
sequence
Predicted mass
of residual CHO Db D, %
% by
massc
1 4630.2 3752.4 877.8 876.8 1.0 0.02 8.1
2 4819.6 3752.4 1067.2 1064.0 3.2 0.07 9.2
3 5000.8 3752.4 1248.4 1242.2 4.5 0.13 3.7
4 5358.2 3752.4 1605.8 1607.5 21.7 20.03 17.9
5 5517.6 3752.4 1765.2 1769.6 24.42 20.08 20.5
6 5677.9 3752.4 1925.5 1931.8 26.3 20.11 17.3
7 5821.1 3752.4 2068.1 2077.9 29.18 20.15 3.7
8 6179.0 3752.4 2426.6 2420.3 6.3 0.10 15.6
9 6353.8 3752.4 2601.4 2598.4 3.0 0.05 4.0
a Mass of the primary sequence of the glycosylated hCGbcf peptide, b6-b40.
b Difference between the calculated mass of the expected total carbohydrate and the inferred mass after subtraction of the mass of the primary sequence from the
peak mass.
c Where the total area under peaks 1–9 in Fig. 2 equals 100%.
Table 2. Relative molecular mass (RMM) of the
monosaccharides expected to be present in hCGb subunit
N-linked carbohydrates.
Monosaccharide RMM RMM 2 H2O
Sialic acid 309.27 291.25
Galactose 180.16 162.14
GlcNAc 221.21 203.19
Mannose 180.16 162.14
Fucose 164.16 146.14
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Table 3. Proposed structures of the oligosaccharides in the glycoforms contributing to the microheterogeneity of hCGbcf.a
a Where the masses found give rise to a variety of carbohydrate combinations on any one peptide, these are shown.
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have been trimmed back to their trimannosyl cores and
smaller sugars (22–26). In addition, de Medeiros et al. (24 )
found that 22–44% of hCGbcf molecules were not bound
by the lectin concanavalin A, and of those 88% were
completely deprived of any carbohydrate content. After
DTT reduction, our MALDI-TOF MS data indicated the
presence of only one nonglycosylated peptide at m/z
4156.8 within the dipeptide molecule. If the usually gly-
cosylated peptide (b6-b40) had been completely lacking
in carbohydrate, then a peak at m/z 3752.4 should have
been apparent in the mass spectrum of reduced hCGbcf.
This peak was not observed at all in any of the spectra
Fig. 3. MALDI-TOF mass spectrum of purified hCGbcf in SA matrix generated by summation of the signals from 40 laser shots and calibrated
externally using horse heart cytochrome C (Mr 12 360.1).
Fig. 4. MALDI-TOF mass spectrum of hCGbcf after “on-target” DTT reduction and using SA matrix.
The spectrum was generated by summation of the signals from 30 laser shots and calibrated internally using fragment mass [M1H]1 4156.8. Peaks 1–9 are described
in the text.
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acquired from reduced hCGbcf. Additionally, our MALDI
analysis of hCGbcf confirms the lack of sialic acid as
expected but also the lack of any galactose in this prepa-
ration.
The galactose content of hCGbcf has been reported
differently. Direct carbohydrate analyses after acid hydro-
lysis (24 ) or conversion of sugars to glycamines (23 ) has
detected small amounts of galactose. Conversely, indirect
analysis has found hCGbcf N-linked sugars lacking in the
monosaccharide (22, 25). The observation that hCGbcf is
not bound by galactose-specific Ricinus communis agglu-
tinin-agarose affinity matrix (23, 25) has been attributed
to the inability of the matrix to bind one galactose residue
per N-linked sugar, whereas contaminating glycoprotein
is thought to account for hCGbcf galactose detected
directly (22 ). This direct MALDI-TOF MS analysis indi-
cated that no galactose was present in the N-linked sugars
of the sample we investigated. It is uncertain where the
degradation of hCG carbohydrates occurs. In their study
of hCGb separated from intact urinary hCG, Liu and
Bowers (7 ) detected a range of both sialated and asialo
mono-, bi-, and triantennary N-linked oligosaccharides. It
would therefore seem likely that the majority of sialic acid
and galactose residues are lost as hCG is processed to
hCGbcf after renal reabsorption. Whether or not this is the
case, our results indicate that hCGbcf possesses neither
sialic acid nor galactose residues. In fact, the glycoforms
that appear to be present in hCGbcf range from a single
GlcNAc residue to more complex structures extending
beyond the trimannosyl core. The largest carbohydrate
structures inferred by our results, peaks 8 and 9 in Fig. 4,
may arise from degraded forms of the sugars II and IV in
Fig. 1, determined by Elliott et al. (14 ) in hCGb.
Absolute quantification of the relative amounts of each
N-linked carbohydrate moiety was not possible using this
method. Semiquantification of relative amounts of glyco-
form pairs was possible by determining the areas under
the peaks of the reduced peptides. Unfortunately, many
peaks could have arisen from multiple combinations of
sugars. However, the monosaccharides determined from
peak 8 (see Table 3) give rise to a combination of only two
carbohydrates moieties that may arise from shortened
triantennary oligosaccharides. This peak comprised 15.6%
of the carbohydrate content of this sample, which is in
agreement with the triantennary content of normal preg-
nancy hCG b-subunits as determined by Elliott et al. (14 ).
Because the crude preparation from which this hCGbcf
was prepared may have contained urinary hCGb from
not necessarily normal pregnancies, it is impossible to say
whether the larger sugar moieties we observed originated
from either the triantennary carbohydrate (IV in Fig. 1)
seen in normal or aberrant pregnancies or the biantennary
sugar (II in Fig. 1) observed almost exclusively in gesta-
tional diabetes (14 ).
In conclusion, the percentage abundance of other glyco-
forms detected by MALDI-TOF MS indicates that it is
likely that the microheterogeneity of the hCGb N-linked
carbohydrates found by Elliott et al. (14 ) is conserved in
hCG b-core fragments from all normal and aberrant
pregnancies. Although not precisely defining hCGbcf
glycosylation, the MALDI-TOF mass spectrum of DTT-
reduced hCGbcf produces what appears to be a distinc-
tive “fingerprint”. For example, peaks of higher mass
attributable to the increased triantennary sugar content of
hCGbcf would be expected to increase in area in the
spectra of hCG b-core fragments from individuals with
abnormal or Down syndrome pregnancies and choriocar-
cinoma. Until now, definitive testing for hyperglycosyla-
tion in hCG in patient urine has required multiple precip-
itation and chromatographic steps (31 ) followed by thiol
reduction, glycan release, and HPLC (14 ). This is an
approach that may be considered too time-consuming for
routine clinical biochemistry. Although an extract of
hCGbcf was analyzed in our current investigation,
MALDI-TOF MS analysis of unextracted urine samples
from pregnant women shows a broad peak corresponding
to protonated hCGbcf, indicating that its concentration in
pregnancy urine is sufficiently high for detection pur-
poses. Further study will help to elucidate whether the
reductive technique described here can be applied to
pregnancy or choriocarcinoma urine, possibly after de-
salting and concentration by centrifugal ultrafiltration
(10 ). The potential clinical utility for distinguishing be-
tween normal pregnancy and Down syndrome pregnancy
by this approach needs to be demonstrated and is cur-
rently under investigation.
This ongoing project is funded by the Joint Research
Board of St. Bartholomew’s Hospital, London.
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